Latest Headlines

Latest Headlines

Celgene's superstar Revlimid again dissed by U.K. cost watchdog

Celgene is working to expand its portfolio of drugs, but for now its growth is primarily driven by extending the uses of its megablockbuster Revlimid. As successful as the myeloma drug has been, the U.K.'s NICE is again questioning its cost vs. benefit for certain patients.

DOJ declines to join whistleblower lawsuit against Celgene

New Jersey-based Celgene in 2011 tucked a notice into a financial report that a U.S. Attorney in California was investigating its marketing of its cancer meds Revlimid and Thalomid. Nothing more was said until Thursday when the company divulged that the probe was tied to lawsuits filed against it by whistleblowers.

Celgene raises earnings forecast third time

Celgene CFO Jacqualyn Fouse recently noted the markets have been rewarding the biotech for plainly explaining how its pieces fit together to reward investors. That comfort with the company came into play again today when its shares were unfazed even though it reported lower net income on higher expenses. Investors were placated when the Summit, NJ-based company raised its earnings forecast for the year for the third time.

Celgene powers on toward aggressive 2017 goal

Celgene CEO Bob Hugin raised some eyebrows at the JP Morgan investor conference in January when he said the company would double sales to $12 billion by 2017. But his remarks look less like boosting with each passing earnings report as the company's small stable of drugs keeps churning out enough cash for the drugmaker to ratchet up projections.

Top 20 orphan drugs by 2018

For a long time, pharma companies have looked to large disease populations as the biggest potential revenue streams. But those days are long gone. That perception has shifted, especially with the prescription drug market stagnating in the U.S. and Europe. Orphan drugs--pharmaceutical treatments for rare diseases or disorders--have proven themselves as viable moneymakers, and the industry has taken note. Read the report >>

Deaths force Celgene to stop Revlimid CLL trial in its tracks

Today, Celgene said it halted a trial testing Revlimid as a first-line treatment for elderly patients with B-cell chronic lymphocytic leukemia, or CLL. The reason: almost twice as many deaths in Revlimid patients as in control patients.

UPDATED: Celgene hits new bump in extending Revlimid sales

Celgene's blood cancer drug Revlimid was cruising in the first half of 2013. Now, the U.K.'s cost-effectiveness watchdog has put up a roadblock, but some new positive trial data might keep the setback from taking too much wind out of Revlimid's sails.

Celgene wins China's blessing for Revlimid launch

Celgene's ($CELG) blood cancer drug Revlimid is on a roll. Already a blockbuster with $3.77 billion in 2012 sales, Revlimid has snagged an approval from Chinese regulators. And the FDA put the drug up for priority review for a new use in patients with mantle-cell lymphoma.

New Celgene drug packs punch for multiple myeloma market

The market for multiple melanoma drugs has been forecast to grow 60% by 2021, reaching more than $7 billion from about $4.4 billion. That growth will be powered by approvals of new therapies to supplement drugs like Takeda's market leading Velcade and Celgene's Revlimid.

Celgene keeps biotech spotlight with sanguine Abraxane data in pancreatic cancer

Celgene CEO Bob Hugin is leading a push to rapidly grow the major drugmaker, keeping the company atop lists of go-to partners among biotechs.